MetaCap

Larimar Therapeutics Inc. Company Profile

NASDAQ: LRMRHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.14-0.08 (-2.48%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

Larimar Therapeutics at a glance

Larimar Therapeutics Inc. (NASDAQ: LRMR) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Bala Cynwyd, PA. Larimar Therapeutics is led by Dr. Carole S. Ben-Maimon M.D. and employs about 71 people. The company's shares have traded publicly since 2014.

At a market capitalization of $328.6 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001374690, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Larimar Therapeutics do?

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.

Business description based on the company's public filings.

Company information

Legal name
Larimar Therapeutics Inc.
Ticker
NASDAQ: LRMR
Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Carole S. Ben-Maimon M.D.
Employees
71
Headquarters
Three Bala Plaza East, Bala Cynwyd, PA, United States
Phone
844 511 9056
IPO year
2014
Market cap
$328.55M
SEC CIK
0001374690
Latest annual report
10-K · Mar 19, 2026

Companies similar to Larimar Therapeutics

LRMR peer companies
CompanyPrice% ChgMarket capCompare
INOInovio Pharmaceuticals Inc.1.76+2.92%$329.66Mvs LRMR
MPLTMapLight Therapeutics Inc.5.94-7.48%$330.12Mvs LRMR
AVIRAtea Pharmaceuticals Inc.3.96+0.76%$318.00Mvs LRMR
CTNMContineum Therapeutics Inc. Class A8.68-3.98%$340.83Mvs LRMR
PEPGPepGen Inc.3.78-3.82%$356.31Mvs LRMR
SPRYARS Pharmaceuticals Inc.2.96-11.90%$297.56Mvs LRMR
ASPEAspen Neuroscience Inc.12.42+0.24%$361.16Mvs LRMR
PBYIPuma Biotechnology Inc7.05-0.98%$364.47Mvs LRMR

Related